Dexcom Director Glenn S. Boehnlein Awarded 5,841 RSUs
DEXCOM INC
Subscribe to track DXCM
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Dexcom Inc. ($DXCM) — Form 4 Filing Insider: Glenn S. Boehnlein (Director) Transaction: Grant of 5,841 Restricted Stock Units (RSUs) at $0.00 Total Value: $0.00 (Equity Award) Direct Shares Held Post-Transaction: 5,841 Indirect Shares Held Post-Transaction: 42 (via Trust) Significance: Low (Routine Director Equity Grant)
Comprehensive Analysis
Executive Summary
On September 10, 2026, Dexcom, Inc. ($DXCM) director Glenn S. Boehnlein reported an acquisition of 5,841 shares of Common Stock in the form of Restricted Stock Units (RSUs) with a transaction price of $0.00. Following the transaction, Mr. Boehnlein directly holds 5,841 shares and indirectly holds 42 shares via the Boehnlein 2017 Trust.
Transaction Details
- Security: Common Stock (Restricted Stock Units)
- Transaction Code: A (Award/Grant)
- Shares Acquired: 5,841
- Price per Share: $0.00
- Vesting Terms: Vests in three equal annual installments starting from the grant date.
- Post-Transaction Holdings: 5,841 direct shares / RSUs and 42 indirect shares.
Market & Governance Context
This filing represents a routine director compensation equity grant exempt under Section 16b-3. Because it is a scheduled equity award rather than an open-market purchase or sale, it carries low trading significance for market sentiment.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.